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Polycystic ovary syndrome (PCOS) remains one of the most common endocrine
disorder in premenopausal women with an unfavorable metabolic risk profile. Here, we
investigate whether biochemical hyperandrogenism, represented by elevated serum free
testosterone, resulted in an aberrant circulating microRNA (miRNAs) expression profile
and whether miRNAs can identify those PCOS women with metabolic syndrome (MetS).
Accordingly, we measured serum levels of miRNAs as well as biochemical markers
related to MetS in a case-control study of 42 PCOS patients and 20 Controls. Patients
were diagnosed based on the Rotterdam consensus criteria and stratified based on
serum free testosterone levels (≥0.034 nmol/l) into either a normoandrogenic (n = 23)
or hyperandrogenic (n = 19) PCOS group. Overall, hyperandrogenic PCOS women
were more insulin resistant compared to normoandrogenic PCOS women and had a
higher prevalence of MetS. A total of 750 different miRNAs were analyzed using TaqMan
Low-Density Arrays. Altered levels of seven miRNAs (miR-485-3p, -1290, -21-3p, -139-
3p, -361-5p, -572, and -143-3p) were observed in PCOS patients when compared
with healthy Controls. Stratification of PCOS women revealed that 20 miRNAs were
differentially expressed between the three groups. Elevated serum free testosterone
levels, adjusted for age and BMI, were significantly associated with five miRNAs (miR-
1290, -20a-5p, -139-3p, -433-3p, and -361-5p). Using binary logistic regression and
receiver operating characteristic curves (ROC), a combination panel of three miRNAs
(miR-361-5p, -1225-3p, and -34-3p) could correctly identify all of the MetS cases within
the PCOS group. This study is the first to report comprehensive miRNA profiling in
different subgroups of PCOS women with respect to MetS and suggests that circulating
miRNAsmight be useful as diagnostic biomarkers of MetS for a different subset of PCOS.
Keywords: microRNA, polycystic ovary syndrome, serum free testosterone, hyperandrogenism, metabolic
syndrome, TaqMan low density arrays
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INTRODUCTION
Polycystic ovary syndrome (PCOS) presents with a multifactorial
etiology that includes genetic predisposition (1) and
environmental factors. PCOS is the most common endocrine
disturbance in women and has a prevalence of 6.1–19.9% among
women in the reproductive-age (2). According to the Rotterdam
criteria, PCOS is diagnosed, when two out of the three following
criteria are fulfilled: (1) Oligo- or anovulation, (2) Clinical and/or
biochemical signs of hyperandrogenism, and (3) Polycystic
ovaries and exclusion of other etiologies (such as congenital
adrenal hyperplasia, androgen-secreting tumors, Cushings’
syndrome) (3–5).
Elevated androgen levels constitute a key feature in the
pathogenesis of PCOS (5) with high testosterone (T) levels
being linked with abdominal fat distribution (6), glucose
intolerance (5), and insulin resistance (5) as well as ovulatory
dysfunction (7). Both androstenedione and T contribute to the
total circulating androgen pool. A large cohort study of PCOS
women showed that elevated free T levels conferred increased
metabolic risk compared to PCOSwomen with isolated increased
androstenedione (8). Normoandrogenic oligo- or anovulatory
patients with polycystic ovaries often have a milder metabolic
profile that more closely resembles that of control subjects (9, 10).
The clinical indication of hyperandrogenism, scored by Ferriman
Gallwey (FG), varies by ethnicity, sensitivity of the hair follicles
to androgens (11) as well as the biochemical level of circulating
androgens. Thus, FG-score correlates only modestly with
total serum T (12). Furthermore, hyperandrogenemia, but not
hirsutism, was found to be an independent predictor of metabolic
syndrome (MetS) presence in PCOS patients (13). Given that
PCOS women already have an unfavorable metabolic profile in
early adulthood, there is a need for PCOS patient stratification in
terms of metabolic risk outcomes independently of the different
PCOS phenotypes.
Circulating microRNA (miRNA) profiles may constitute
valuable screening tools as non-invasive biomarkers as they
are abundant in serum, resistant to nucleases and stable over
freeze-thaw cycles. Sensitive and specific reverse-transcription
polymerase chain reaction (RT-qPCR)-based assays for their
detection suggest miRNAs as promising biomarker candidates
(14). In cells, miRNAs post-transcriptionally impair mRNA
translation and, consequently, a dysregulated miRNA expression
profile may affect various cellular processes and pathways,
in keeping with the complexity of PCOS (15). Moreover,
alterations in the circulating miRNA profile may reflect
underlying changes in miRNA expression in or secretion from
several tissues.
Research concerning miRNAs in serum of PCOS patients
is limited; at the present time, few studies examine this
topic (16–24). There is consensus that a miRNA profile
has the ability to distinguish between PCOS patients and
controls. However, there is only limited agreement on
which miRNAs that could serve as markers of PCOS (15),
although miR-21 and miR-93 have received attention by
several groups as being involved in the pathogenesis of PCOS
(25–31). Circulating miRNAs may also (in time, given further
investigations) present as valuable informants about various
pathophysiological processes occurring in remote and potentially
inaccessible tissues.
In view of these findings, the present study evaluates, in an
unbiased and comprehensive fashion, how miRNAs in serum
relate with PCOS in Danish women. Furthermore, because of the
significant role of hyperandrogenemia in many aspects of PCOS,
patients were categorized into biochemical hyperandrogenic or
normoandrogenic PCOS groups to discover more precise links
between different phenotypes of PCOS and the level of circulating
of miRNAs. In this study, we have systematically screened serum
miRNAs from 62 study participants using the TaqMan Low-
Density Array (TLDA) of 750 different miRNAs and determined
their correlation with clinical and metabolic indices found in
PCOS women (n = 42) compared with age as well as in BMI
matched Controls (n = 20). Previous studies have used triage-
based study designs that investigated RNA from a pool of
PCOS patients or only a subset of study participants for TLDA
or sequencing, followed by a validation of selected miRNAs
by individual RT-qPCR in a larger study sample (16, 32). To
our knowledge, this is the first study with a comprehensive
screening of an entire PCOS study population for this number
of different miRNAs.
MATERIALS AND METHODS
Study Population
During January 2010–February 2013, we recruited 42 women
diagnosed with PCOS according to the Rotterdam 2003 criteria
and 20 healthy, age, and bodymass index (BMI) matched, regular
cycling women who were referred to the fertility clinic due to
tubal factor infertility or male infertility. For evaluation purposes,
PCOS women were subdivided according to high or normal free
serum T levels. A PCOS patient with free serum T above 0.034
nmol/l was considered biochemical hyperandrogenic according
to Danish reference intervals (95th percentile) for serum free T
for females aged 11–50 (33, 34). Further details of the population
is given elsewhere (26).
Ethics
This study was approved by the Local Scientific Ethical
Committee of Region Zealand, DK (approval no. SJ-156). The
study was conducted in accordance with the Helsinki Declaration
II and all the participants gave written informed consent before
their inclusion.
Baseline Characteristics
Anthropometric and biochemical measurements obtained in
this study population have been described previously (26, 35).
Serum T, androstenedione, and dehydroepiandrosterone sulfate
(DHEAS) were measured by liquid chromatography-tandem
mass spectrometry (PerkinElmers Inc., USA), sex hormone
binding globulin (SHBG) by an immunometric assay with
fluorescence detection on the Abbott Architect i2000 analyzer.
Estimation of free serum T was obtained based on SHBG
and total T according to Vermeulen et al. (36). Insulin
resistance was indirectly assessed using the homeostatic index
of insulin resistance (HOMA-IR) index according to this
formula: HOMA-IR= [Fasting plasma insulin (mU/L) • Fasting
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plasma glucose (mmol/L)]/22.5. In accordance with current
consensus statements (37), Anti-Müllerian hormone (AMH)
was not included in the present study. MetS was present if
any three of the following criteria was fulfilled according to
International Diabetes Federation consensus statement (38):
(1) waist circumference ≥80 cm, (2) Elevated blood pressure
(≥130/85mmHg), (3) Raised fasting blood glucose≥5.6mmol/L,
(4) DecreasedHDL cholesterol (<1.3mmol/L), and (5) Increased
triglyceride levels (≥1.7 mmol/L).
Sample Preparation and Isolation of
miRNA From Serum
Total RNA was extracted from serum samples with Tri-
reagent LS (Sigma-Aldrich, Brøndby, Denmark), according to
manufacturers’ protocol and stored at −80◦C until analysis.
RNA concentration and purity were assessed using a NanoDrop
ND-1000 (Thermo Fisher Scientific, Hvidovre, Denmark).
MiRNA Serum Profiling
Megaplex RT-primer pools were used to reverse transcribe 125 ng
RNA to cDNA and TaqMan MicroRNA Reverse Transcription
Kit (ThermoFisher Scientific) according to manufacturers’
protocol. The RT-product was pre-amplified with TaqMan R©
PreAmp Master Mix and miRNA PreAmp primer pools. Pre-
amplified samples were diluted with 0.1× TE buffer (pH 8.0) and
stored at −80◦C until analysis. The miRNA profile was acquired
using Human TaqMan Low-Density Array (TLDA) cards v.3
containing 750 unique miRNAs (ThermoFisher Scientific). All of
the TLDA cards had the same lot number to minimize variation.
Expression data were obtained using the ViiA 7 real-time PCR
system and analyzed using QuantStudio software. Amplification
plots were manually inspected and assays with poor or no
amplification (undetectable) were excluded from further analysis
(n = 406). A pre-specified criterion was that a miRNA needed to
be present in at least 10 (15%) of the samples, so as to be included
in further analyses. Data were normalized using the global mean
normalization method (39). Data from this miRNA discovery
profiling would be available upon reasonable request.
Technical Validation of miRNA by Individual
qPCR
A total of 200 ng serumRNAwas reverse transcribed withmature
miRNA-specific stem-loop RT-primers using SuperScript III
(Thermo Fisher Scientific). Subsequently, qPCR was performed
on diluted cDNA using QuantiTect SYBR Green PCR master
mix (Qiagen, Copenhagen, Denmark) as described previously
(26) (oligos are listed in Supplementary Table 1). All reactions
were performed in duplicate. The miRNA levels were normalized
to the expression of miR-484, which showed minimal variation
across samples and experimental groups according to the
NormFinder (40) algorithm (Supplementary Figure 1). MiRNA-
484 has been used by others as a reference and normalization
miRNA (41). This also provided a validation of our TaqMan
(TLDA) data using SYBR Green qPCR chemistry.
Statistical Analyses
Statistical analyses were performed using the Statistical Packages
for Social Sciences (SPSS) vers. 24 or the statistical package R and
R-Studio vers. 3.1.3. A prior power analysis with the given sample
size shows that we have a power of more than 90% to detect a
fold change of 1.5 with a relative SD of 0.4 with a Student’s t-test
(estimated effect size, Cohen’s d, 1.25).
TLDA miRNA relative levels were quantified by the 2−11Ct
method. Validation of the relative expression of individual
miRNAs was quantified by the standard curve method. Normal
distribution was assessed by a Kolmogorov–Smirnov test.
Logarithmic transformation was applied to the non-normally
distributed data. Group means were compared by Student’s t-
test or one-way ANOVA with Tukey’s post-hoc test (two-sided).
Values were reported as mean ± SD or medians (interquartile
range) as appropriate. Pearson correlations were visualized using
the R package corrplot (42). Partial Pearson correlations were
performed to control for the effects of age and BMI. A volcano
plot was plotted to display fold changes (log2) against statistical
t-test p-values (–log10) for each miRNA in relation to PCOS
women and Controls. To adjust for the potentially confounding
effect of age and BMI, binary logistic regression analyses for
the association between each of the miRNA and PCOS or
multinomial logistic regression for the three different groups
were carried out represented by the odds ratio (OR) and 95%
confidence interval (CI).
A p-value of < 0.05 was considered statistically significant.
Adjustment for multiple testing was not found applicable given
the lack of independence of variables (43) [e.g., miRNAs show
a high degree of correlation within groups (44)] in the dataset
and the exploratory nature of the study. GraphPad Prism
vers. 8 (GraphPad Inc., La Jolla, CA, U.S.A.) was used for
figure preparation.
RESULTS
Demographics, Clinical and Biochemical
Markers of the Study Population
Both PCOS women and Controls were well matched for age
and BMI (Table 1). In the PCOS group FG scores, androgens,
luteinizing hormone (LH) were significantly elevated (Table 1).
The biochemical hyperandrogenic PCOS women were more
insulin resistant (p < 0.01) compared to the normoandrogenic
PCOS group. Furthermore, the incidence of MetS was higher in
PCOS women with elevated serum free T (p< 0.05).
Human Serum miRNA Profiles by Array
Analysis
We performed an extensive qPCR based profiling of 750 different
miRNAs in serum from all 62 subjects in our cohort in order
to identify dysregulated miRNAs in PCOS women. Among the
predefined 750 miRNAs, we identified 303 miRNAs (40.4%)
as robustly present in serum. The 10 most abundant serum
miRNAs in the entire study population had similar levels
with miR-518 species being most abundant among circulating
miRNAs (CT ≤ 10.0, Supplementary Table 2). Analyzing the
intercorrelation between the 50 most highly expressed miRNAs
revealed that the majority (n = 41) of the miRNAs correlated
with each other belonging either in one large or in one smaller
cluster (Supplementary Figure 2). Moreover, we evaluated the
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TABLE 1 | Baseline characteristics of study participants.
Control PCOS p Normo PCOS Hyper PCOS p
N 20 42 23 19
Age 27 (7.5) 27 (6.3) NS 29 (7) 27 (6) NS
Height (cm) 166.9 ± 6 169.5 ± 6.1 NS 171.2 ± 6.4 167.3 ± 5.2 NS
Weight (kg) 71.3 (23.8) 72.3 (18.1) NS 71.6 (15) 75 (16.2) NS
Body Mass Index (kg/m2) 25.0 (6.9) 24.4 (5.9) NS 23.8 (4.7) 28.4 (6.2) NS
Waist-to-hip ratio 0.8 ± 0.1 0.8 ± 0.1 NS 0.8 ± 0.1 0.8 ± 0.1 NS
Ferriman–Gallwey (FG) score 1.0 (1.0) 4.0 (6.3) <0.01 4.0 (6.0) 5.0 (6.0) <0.01a,b
Total testosterone (T) (nmol/L) 1.1 (0.5) 2.4 (1.5) <0.01 1.9 (1.1) 3.7 (2.3) <0.01a,b,c
Free testosterone (T) (nmol/L) 0.014 (0.005) 0.025 (0.045) <0.01 0.020 (0.006) 0.066 (0.018) <0.05a,b,c
Sex hormone binding globulin (SHBG)
(nmol/L)
71.0 (36.3) 65.5 (55.8) NS 88.0 (53) 46.0 (36) <0.01a,c
Androstenedione (nmol/L) 4.4 (2.5) 7.7 (4.5) <0.01 5.4 (2.5) 10.1 (4.3) <0.01a,b,c
Dehydroepiandrosterone sulfate
(DHEAS) (nmol/L)
5,291 ± 1,949 5,959 ± 2,473 NS 4,642 ± 1,644 7,554 ± 2,393 <0.01a,c
Follicle-stimulating hormone (FSH) (IU/L) 6.3 ± 1.9 5.6 ± 1.7 NS 5.7 ± 1.9 5.4 ± 1.5 NS
Luteinizing hormone (LH) (IU/L) 5 (3.8) 11.6 (5.9) <0.01 10.8 (6.6) 12 (6.3) <0.01a,b
Estradiol (nmol/L) 0.19 (0.04) 0.2 (0.03) NS 0.2 (0.12) 0.2 (0.01) NS
Prolactin (mIU/L) 212.0 (132) 212.0 (135) NS 237.0 (141) 209.0 (118) NS
Thyroid stimulating hormone (TSH) 1.8 (1.2) 1.7 (1) NS 1.7 (0.7) 1.5 (1.2) NS
Alanine transaminase (ALAT) (u/L) 15.5 (10) 18 (16.5) NS 17 (8) 22 (19) NS
Fasting plasma glucose (mmol/L) 5.0 (0.5) 5.1 (0.5) NS 5.1 (0.4) 5.2 (0.6) NS
Fasting serum insulin (mU/L) 7.7 (5.5) 6.9 (8.1) NS 6.2 (5.6) 8.8 (8.8) <0.01c
Fasting plasma C-peptide (pmol/L) 605(260) 560 (390) NS 470 (270) 680 (390) <0.05a,c
HOMA-IR (mU·mmol·L−2 ) 1.8 (1.3) 1.5 (1.9) NS 1.3 (1.5) 2.1 (2.1) <0.01c
Total cholesterol (mmol/L) 4.4 (1.1) 4.3 (0.9) NS 4.4 (1.3) 4.3 (0.7) NS
LDL cholesterol (mmol/L) 2.6 ± 0.8 2.4 ± 0.7 NS 2.5 ± 0.7 2.4 ± 0.7 NS
HDL cholesterol (mmol/L) 1.6 (0.4) 1.5 (0.5) NS 1.6 (0.5) 1.4 (0.4) <0.05a,c
Triglycerides (mmol/L) 0.6 (0.2) 0.7 (0.5) NS 0.6 (0.3) 1.0 (0.8) <0.05a,c
Metabolic syndrome (yes/no) 1/20 7/35 NS 1/22 6/13 <0.05#
Baseline characteristics of the study participants. Data presented as mean ± SD or as median (interquartile range) if not normally distributed. Biochemical hyperandrogenic (Hyper)
and normoandrogenic (Normo) PCOS patients were defined based on a free T level above or below 0.034 nmol/L, respectively. HOMA-IR, homeostatic model assessment of insulin
resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, not significant.
aSignificant difference between hyperandrogenic patients and Controls after Tukey post-hoc.
bSignificant difference between normoandrogenic patients and Controls after Tukey post-hoc.
cSignificant difference between hyperandrogenic patients and normoandrogenic after Tukey post-hoc.
#Significant difference between hyperandrogenic patients and both normoandrogenic PCOS women and Controls after Fisher’s Exact test. P < 0.05 were consider significant.
variability of the miRNAs in the control women and in the
entire sample set (Supplementary Figure 3). The clear majority
of the circulating miRNAs had an inter-assay coefficient of
variation (CV) of <5%; only 18 out of 303 miRNAs had
a CV >5% (Supplementary Figure 3). Thus, although there
is interpersonal variation in the levels of each miRNA, with
few exceptions, the levels of each species of miRNA appears
quite defined, at least in our specific cohort of PCOS women
and Controls.
Circulating miRNAs Are Able to
Differentiate Between PCOS Patients and
Controls
The potential of each circulating miRNAs (n = 303) to
differentiate between healthy Controls and women with PCOS
was evaluated and is illustrated using a Volcano plot (Figure 1).
Three serum miRNAs (1.0% of detected miRNAs; miR-485-
3p, miR-1290, and miR-7-1-3p) were significantly increased
while eight miRNAs (2.6% of detected miRNAs; miR-21-3p,
-139-3p, -572, -361-5p, -143-3p, -345-5p, -1276, and miR-22-
5p) were significantly decreased in PCOS women compared
with Controls (Figure 1). Half of the miRNAs showed more
than an absolute fold difference of 1.8 between the two
groups. As obesity amplifies and worsens the metabolic and
reproductive abnormalities in PCOS and advanced age gradually
decreases the severity of cardinal features of PCOS, data
for the eleven significant miRNAs were adjusted for the
confounding effects of age and BMI. Both miR-485-3p and
miR-1290 remained significantly associated with increased odds
of having PCOS (p = 0.02, OR 1.5, 95% CI: 1.1–2.2 and p
= 0.02, OR 1.3, 95% CI: 1.0–1.8) with a 1.1 and 1.6 fold
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FIGURE 1 | Volcano plot displaying differences in circulating miRNA levels between PCOS women and Controls. Volcano plot based on miRNA mean fold changes
between PCOS patients vs. Control subjects. Open circles indicate significantly [p < 0.05; –log (p-value) of −1.3, dotted line] increased or decreased relative miRNA
levels of each miRNA in PCOS patients compared to Control subjects.
increase observed in PCOS women compared to Controls
(Figures 2A,B).
As can be seen in Figures 2C–G, miR-21-3p (p = 0.004, OR
0.6, 95% CI: 0.3–0.9), miR-139-3p (p = 0.0004, OR 0.5, 95%
CI: 0.3–0.9), miR-361-5p (p = 0.001, OR 0.4, 95% CI: 0.2–0.9),
miR-572 (p = 0.005, OR 0.3, 95% CI: 0.1–0.8), and miR-143-3p
(p = 0.01, OR 0.3, 95% CI: 0.1–0.9) all remained significantly
associated with decreased odds of having PCOS. All five miRNAs
were decreased by 1.7-fold or more, except miR-143-3p, in PCOS
patients compared to Controls. Levels of the remaining four
miRNAs can be found in Supplementary Figure 4.
To confirm the results obtained by the arrays a
technical validation was performed for miR-485-3p
(Supplementary Figure 5). In the arrays, miR-485-3p was
elevated in PCOS women (Figure 2A, p= 0.004). The individual
qPCR showed thatmiR-485-3pwas indeed significantly increased
in PCOS patients compared with the Controls (p< 0.001).
Dysregulated Circulating miRNAs in PCOS
Women Subsets
Evaluation of miRNAs defining the normoandrogenic
and hyperandrogenic PCOS patient subsets and Controls
showed that 20 miRNAs were expressed differently within
the three groups after age and BMI correction (Figure 3
and Supplementary Figure 6). Given that several of the
miRNAs showed similar expressions and a high degree
of correlation between individual miRNAs, a subset of
these are shown in Figures 3A–H. In women with normal
free T levels, miR-485-3p was found elevated by 1.3-fold
compared to Controls (p < 0.05, Figure 3A). Despite also
being increased in hyperandrogenic PCOS women, this
comparison was not significant. A gradual increase in miR-
1290 levels (p < 0.05, Figure 3B) as well as a 2-fold increase
of miR-20a-5p (p < 0.05, Figure 3C) were observed in the
hyperandrogenic PCOS women. Circulating miR-139-3p was
also significantly decreased in both PCOS subsets compared
to healthy Controls with the more hyperandrogenic PCOS
women displaying the largest reduction (1.9- vs. 1.7-fold,
p < 0.05, Figure 3D). Normoandrogenic PCOS women and
Controls had similar levels of miR-433-3p while it being
2-fold less abundant in hyperandrogenic PCOS patients
compared to either group (p < 0.05 or p < 0.01, Figure 3E).
In comparison to Controls, miR-361-5p decrease gradually
the more hyperandrogenic the PCOS women were (2.9-fold,
p < 0.01, Figure 3F). Both miR-34b-3p and miR-1225-3p were
increased in normoandrogenic PCOS patient either compared
to hyperandrogenic PCOS women or Controls (p < 0.05,
Figures 3G,H).
The remaining dysregulated miRNAs between the two
PCOS subsets and Controls, which were still significant
after adjustments for BMI and age, are displayed in
Supplementary Figure 6.
Circulating miRNAs Correlate With
Androgens and Biochemical Markers of
Metabolic Syndrome
The relationship between circulating miRNA, androgens and
biochemical markers of MetS was explored by correlation
analysis controlling for the effects of BMI and age in the entire
cohort (Table 2). Hyperandrogenism (in the form of either
total T, free T, DHEAS or androstenedione) was positively
associated with miR-1290 (r range: 0.47–0.35) and miR-20a-5p
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FIGURE 2 | Levels of circulating miRNA species in PCOS patients compared with Control subjects (A–G). Relative fold changes in miRNA quantities normalized to the
global mean. Means and standard deviations are displayed. All indicated p-values were determined by Student’s t-test on log2 transformed data. Data were adjusted
for age and BMI. p-value * < 0.05, ** < 0.01, *** < 0.0001.
(r range: 0.39–0.30). In contrast, miR-139-3p (r range: −0.41
to 0.37), -433-3p (r range: −0.51 to 0.35), -361-5p (r range:
−0.48 to 0.34), and -34b-3p (r = −0.43 to 0.29) correlated
negatively with hyperandrogenism. Furthermore, SHBG, which
is generally low in PCOS, was positively correlated with miR-
361-5p (r = 0.37, p = 0.038) and miR-433-3p (r = 0.36, p
= 0.013). Fasting glucose was modestly associated with miR-
20a-5p (r = 0.32, p = 0.022). Both serum insulin (r = −0.50)
and HOMA-IR (= −0.50) levels correlated negatively with
miR-1225-5p (p = 0.001). Biochemical markers of MetS such
as total cholesterol, HDL cholesterol, and triglycerides were
associated with miR-433-3p (r = 0.41, p = 0.005) and miR-361-
5p (HDL: r = 0.39, p = 0.027, and triglycerides: r = −0.37,
p = 0.036). Lastly, miR-1290 and HDL cholesterol (r = −0.28,
p = 0.042) correlated with each other. Thus, we observed a
multitude of correlations between levels of specific circulating
miRNAs and features of biochemical hyperandrogenism and
the MetS.
Diagnostic Capabilities of Circulating
miRNA
The observed frequency of MetS was significantly higher in the
hyperandrogenic PCOS patients, which led us to verify whether
potential differences in these 20 circulating miRNAs (Figure 3
and Supplementary Figure 6) could be used to distinguish
the presence of MetS in PCOS women. Initially, receiver
operator characteristic (ROC) curves were constructed and
area under the curve (AUC) values for each miRNA were
evaluated (Supplementary Table 3). For PCOSwomen, as shown
in Figure 4A, miR-361-5p was the best independent predictor
of MetS (AUC 0.92, 95% CI 0.79–1.0) followed by miR-1225-
3p (AUC 0.82, 95% CI 0.65–0.99) and miR-34b-3p (AUC 0.77,
95% CI 0.58–0.96). A biomarker panel was constructed using a
combination of the three miRNAs and binary logistic regression
analysis. The 3-miRNA panel had an AUC of 0.96 (95% CI 0.90–
1.0) and correctly classified all of the seven cases of MetS found
in the PCOS group.
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FIGURE 3 | Circulating miRNAs different between healthy, normal cycling Control women, and normo- or hyperandrogenic PCOS patients (A–H). Shown are the
relative fold changes of the significantly identified miRNA levels normalized to the global mean, and displayed as relative to the Control group. All indicated p-values
were determined by one-way ANOVA with a post-hoc Tukey test on log2 transformed data. Data were adjusted for age and BMI. p-value * < 0.05 and ** < 0.01.
Normo, biochemical normoandrogenic PCOS; hyper, biochemical hyperandrogenic PCOS.
Serum free T was significantly elevated in PCOS women
with MetS compared to PCOS women without MetS [mean
(SD):0.069 (0.034) vs. 0.036 (0.024), p = 0.004]. We therefore
also investigated the ability of serum T to predict MetS among
PCOS women. The discriminatory ability of serum free T
alone in relation to MetS in PCOS women was found to be
specific (100% specificity), but also to display a low sensitivity
of just 14% yielding an AUC of 0.78 (95% CI 0.60–0.96)
(Figure 4B). The low sensitivity was observed, because only six
out of the twenty hyperandrogenic PCOS women had MetS.
Addition of serum free T in the logistic regression model
did not significantly improve the AUC of the model and was
therefore not included in the combined model (data not shown).
Further, the miRNA profile between the two PCOS subsets
(normoandrogenic vs. hyperandrogenic) was markedly different
(Supplementary Figure 7), which underlines the heterogeneity
in phenotypes among women with PCOS.
DISCUSSION
To date, this is the largest explorative study of serum miRNA
profiles in PCOS patients and Controls. Its major strength
is the employment of comprehensive array measurements
in all individual samples from the study population. Using
this approach, we identified two (miR-485-3p and miR-1290)
circulating miRNAs with increased levels and five miRNAs (miR-
21-3p, -139-3p, -361-5p, -572, and -143-3p) with lower levels
in PCOS patients compared to control subjects independent
of age and BMI. Furthermore, twenty miRNAs; eight of
which were further analyzed (miR-20a-5p, -34b-3p, -139-
3p, -361-5p, -433-3p, -485-3p, -1225-3p, and miR-1290) had
different levels between either the two PCOS subset or between
healthy Controls and one of the PCOS subsets (Figure 3 and
Supplementary Figure 6). Additionally, clinical variables related
to PCOS, such as free T, DHEAS, and androstenedione were
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TABLE 2 | Correlations between biochemical variables and miRNA levels.
Clinical
variable
miRNAs r r adjusted p p adjusted
Total T miR-1290 0.403 0.399 0.002 0.003
miR-139-3p −0.426 −0.410 0.003 0.005
miR-361-5p −0.369 −0.340 0.032 0.057
miR-34b-3p −0.295 −0.286 0.042 0.054
Free T miR-1290 0.373 0.351 0.005 0.009
miR-20a-5p 0.364 0.302 0.006 0.028
miR-139-3p −0.330 −0.368 0.023 0.013
miR-433-3p −0.492 −0.512 0.0004 0.0003
miR-361-5p −0.515 −0.461 0.002 0.008
SHBG miR-20a-5p −0.289 −0.153 0.031 0.269
miR-433-3p 0.301 0.358 0.036 0.013
miR-361-5p 0.419 0.369 0.014 0.038
DHEAS miR-34b-3p −0.412 −0.425 0.004 0.003
Androstenedione miR-1290 0.493 0.468 0.0001 0.004
miR-20a-5p 0.385 0.393 0.004 0.004
miR-433-3p −0.335 −0.353 0.02 0.016
miR-361-5p −0.465 −0.478 0.006 0.007
Fasting glucose miR-20a-5p 0.273 0.317 0.046 0.022
miR-139-3p −0.306 −0.262 0.039 0.086
Fasting insulin miR-20a-5p 0.326 0.177 0.016 0.209
miR-361-5p −0.458 −0.312 0.006 0.082
miR-1225-3p −0.424 −0.502 0.005 0.001
HOMA-IR miR-20a-5p 0.347 0.212 0.01 0.132
miR-361-5p −0.470 −0.335 0.005 0.061
miR-1225-3p −0.427 −0.501 0.005 0.001
Total cholesterol miR-433-3p 0.336 0.405 0.018 0.005
HDL cholesterol miR-1290 −0.296 −0.280 0.028 0.042
miR-361-5p 0.442 0.390 0.009 0.027
Triglycerides miR-20a-5p 0.401 0.268 0.002 0.052
miR-361-5p −0.476 −0.372 0.004 0.036
Correlation between selected serum miRNAs and baseline characteristics. MiRNA levels
(normalized to the global mean) were log2 transformed prior to analysis. Some of
the biochemical parameters were also log2 transformed prior to analysis as described
in Materials and Methods. Indicated Pearson correlation coefficients are significant at
p < 0.05, p adjusted = Controlling for the effects of age and BMI using partial Pearson
correlation analysis. T, Testosterone; SHBG, Sex hormone-binding globulin.
correlated with the miRNAs suggesting their involvement in
the pathophysiology of PCOS and its intermediary phenotypes
(Table 2). We also observed that five miRNAs (miR-20a-5p,
1225-3p, -433-3p, -1290, and -361-5p) were associated with either
aberrant glucose homeostasis or dyslipidemia. Importantly,
a 3-miRNA panel consisting of miR-361-5p, -1225-3p, and
miR-34b-3p was able to discriminate between MetS in PCOS
women independently of androgen status in terms of serum
free T.
Since qPCR arrays were performed in all individuals, which
to our knowledge has not been done before in relation to PCOS,
we were able to determine that a high degree of correlation
exists between individual miRNAs (absolute Pearson correlation
coefficients ≥0.7, Supplementary Figure 2) suggesting a
FIGURE 4 | Individual microRNAs are predictive of metabolic syndrome in
PCOS women. Receiver operator characteristic curves based on microRNA
levels (normalized to global mean). Shown are three microRNAs as well as a
combination of these distinguishing between metabolic syndrome cases and
those without in the PCOS group (A). Additionally, area under the curves
(AUCs) for serum free testosterone compared to the 3-miRNA signature within
the PCOS group are displayed (B). The corresponding AUCs and 95% CI:
intervals can be found in Supplementary Table 3.
miRNA:miRNA network and potential co-regulation of certain
miRNAs or a common cellular origin of most of the circulating
miRNAs. Also, in our specific cohort of PCOS women and
Controls, most of the miRNAs displayed a low degree of
inter-individual variability, which allows for relatively good
power to detect miRNAs that are different between PCOS and
control women (Supplementary Figure 3). In recent years,
miRNAs have gained increasing attention based on their
application in biomarker studies and as much as 30 different
serum miRNAs have been identified to be involved in PCOS
(16–24), combined with an additional four miRNAs in whole
blood (29), and miR-93 in plasma (25). However, only a few
studies have aimed to identify/characterize miRNAs associating
with PCOS subphenotypes.
It is well established that PCOS is associated with defects
in insulin secretion and profound insulin resistance (45).
The mitochondrial biogenesis master regulator; peroxisome
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proliferator-activated receptor γ coactivator 1α (PGC-1α) is
required to maintain insulin-mediated signaling as well as
mitochondrial function and integrity, thus underscoring its
importance in the development of insulin resistance (46).
Reduced levels of PGC-1α have been found in PCOSwomen (47).
Of interest, miR-485-3p has been shown to target PGC-1α (48);
thus it could be speculated that increased levels of miR-485-3p
in PCOS women could inhibit PGC-1α and subsequently impart
insulin resistance. Moreover, miR-378a-5p, increased in serum
of hyperandrogenic PCOS patients (Supplementary Figure 6B),
is located within the gene encoding PGC-1β (PPARGC1B) and
causes hepatic insulin resistance by targeting the catalytic subunit
of PI3 kinase (49), while simultaneously opposing the actions of
PGC-1β (50), suggesting further links between PCOS associated
miRNAs and insulin resistance.
Profiling of miRNAs in human follicular fluid identify miR-
1290 among the highest expressed miRNAs (51) although not
differentially expressed between PCOS women and controls as
was observed in the current study. Increased circulating miR-
1290 has been reported for various cancers (52, 53) as well as
gestational diabetes (54) and non-alcoholic fatty liver disease
(NAFLD) (55). Potential predicted targets of miR-1290 are the
transforming growth factor β (TGF-β) 2 and 3 as well as the
downstream mediators Smad-2,−5,−7, and−9. Dysregulated
TGF-β signaling pathway in PCOS pathophysiology has been
reported (56–59).
Encoded within the miR-17–92 cluster, miR-20 has been
shown to modulate the TGF-β pathway, the E2F transcription
family (E2F1-3), the insulin gene enhancer protein (Isl-1), the
T-box 1 protein (Tbx1) reviewed by Mogilyansky and Rigoutsos
(60); all of which have been linked to PCOS pathophysiology (61).
Out of the seven PCOS-specific miRNAs, miR-21; which was
downregulated in our study, has been reported to be increased in
serum from PCOS women (23). The observed discrepancy, could
partly, be explained by the fact that the included PCOS women
in the study by Jiang et al. (23) had a higher BMI compared
to controls. Adding to this, obesity was shown by Murri et al.
to increase the expression of whole blood miR-21 in PCOS
women (29). In support of our findings, reduced serum miR-
21 was observed in hyperandrogenic PCOS women, although
not significant, by Naji et al. (62) and low plasma miR-21 was
demonstrated in type 2 diabetic subjects (63).
Our work revealed a downregulated expression of miR-34b-
3p in biochemical hyperandrogenic PCOS women compared
to PCOS women with normal serum free T levels (Figure 3).
A study on the clinical relevance of miR-34b-3p, although in
relation to prostate cancer, revealed that miR-34b-3p could
control transcription of the androgen receptor (AR) in vitro.
Moreover, high tissue expression of AR protein correlated with
low miR-34b-3p levels (64). Given the importance of androgens
and the androgen receptor in the pathogenesis of PCOS (65),
it could be speculated that the low expression of miR-34b-3p
observed in the hyperandrogenic PCOS women could enhance
expression of AR thereby resulting in dysregulated androgen
metabolism. Our results provide a basis for pursuing studies
on the functional consequence of altered miRNAs in terms of
subphenotypes of PCOS.
Elevated circulating vascular endothelial growth factors
(VEGF) may, partly contribute to the highly vascularized and
dense hyperechogenic stroma observed in ovaries of PCOS
women. Furthermore, insulin can stimulate VEGF secretion
while high levels of VEGF have been associated with occurrence
and severity of ovarian hyperstimulation syndrome (OHSS) in
women with PCOS and negative conception rates augmenting
its role in PCOS pathophysiology (66). Low levels of miR-361-5p
in our PCOS women; lowest in hyperandrogenic PCOS women
(Figures 2, 3), could contribute to increased levels of VEGF-A
which is an identified target of miR-361-5p (67).
Prediabetic individuals presented with lower levels of
circulating miR-572 compared to newly diagnosed type 2 diabetic
patients, although not with lower levels than individuals with
normal glucose tolerance (68). It could be speculated whether a
decrease in miR-572, as observed in our study, could serve as a
biomarker for early detection of prediabetes in PCOS women.
We here demonstrate that serum levels of miR-433-3p
significantly differed between hyperandrogenic PCOS women
and Controls and normoandrogenic PCOS women (Figure 3). A
recent study in pancreatic β-cells showed that miR-433-3p had
a protective effect toward glucose toxicity (69) thus low levels
of miR-433-3p could contribute to the increased risk of type 2
diabetes observed in PCOS women.
To the best of our knowledge, no studies with relations to
PCOS have found a mechanism by which elevated miR-1225-3p
or decreased miR-139-3p could be involved in PCOS. Regardless
of mammalian species, miR-143 is among the most predominate
miRNAs expressed in the ovary (70). Dysregulated miR-143, in
mouse models, has been implicated in obesity-associated insulin
resistance (71), in the formation of primordial follicles (72) and
progesterone release (73).
As stated earlier, miR-93 has received attention from several
groups (25, 27, 62, 74). We observe that miR-93-3p is borderline
decreased in PCOS women compared to Controls (p = 0.051)
thus in contrast to increased circulating plasma levels of miR-93
isolated from PCOSwomen (25). At present, it is unclear whether
differences in pre-analytic strategies, mainly normalization,
account for the variable findings or whether these findings are
due to differences in study populations.
The nature of the current study was to investigate the miRNA
profile in serum. We do not know the pathophysiological actions
or mechanisms that regulate the serum miRNA profile, nor the
tissues from which circulating miRNAs originate. However, it is
apparent that a varied tissue distribution of miRNAs exists. The
miRNAs present in serum are the result of secretion of these into
the circulation by various tissues and cells. Identification of their
cellular origin can be difficult. Two studies have compiled a list
of miRNA abundance and tissue-specific distribution (75, 76).
Ludwig et al. investigated only tissues derived from male donors,
which limits any evaluation of the contribution of the female
reproductive tissues to the total miRNA pool found in serum
(76). However, all of the miRNAs differentially expressed in our
study could be identified in all of the tissues examined by Ludwig
et al. with the exception of miR-720, miR-661, and miR-1225-3p
(76). A possible explanation as to why miR-720 was not reported
could be that it is not a bonafide miRNA, but a tRNA fragment
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(77). When interpreting miRNA profiling results obtained from
serum, it is likely that at least some of these may reflect a direct
effect from blood cells. It would be very relevant to investigate the
tissue source of these miRNAs, which possibly could be done by
the capture of exosomes using tissue-specific surface markers.
Packaging of miRNAs into microvesicles, as a way to
protect the miRNAs in the circulation but also contributing to
intercellular signaling, has emerged as a new and interesting
field of study. In this context, circulating platelet-derived
microparticles were found elevated in both lean and obese
women with PCOS compared with controls (78, 79) and
these correlated with serum T. The increased concentration
of microparticles has also been associated with HOMA-IR in
PCOS subject (80). Moreover, the PCOS associated miR-485-
3p was shown to be preferentially packaged into circulating
exosomes (81).
Prevalence rates of MetS are higher in women with PCOS
compared with the general female population. It is well known
that MetS is associated with an increased risk of developing type
2 diabetes and most of these metabolic risk factors are present in
PCOS as well. Abnormal levels of miRNAs in relation to MetS
or to pathophysiological components hereof have been reported
(82–84). Given the public health implications of MetS, early
identification is warranted in order to target early interventions.
Our three candidate miRNA signature (miR-361-5p, -1225-3p,
andmiR-34b-3p) had a 97.1% sensitivity and 85.7% specificity for
identifying MetS in PCOS. Additionally, serum free T levels are
higher in PCOS with MetS compared to PCOS women without
MetS (85). Interestingly, serum free T did not increase the
AUC, when combined with miRNAs thus there is no significant
additional influence of serum free T compared to the 3-miRNA
signature alone. We acknowledge that the ROC curve evaluation
of the prediction model in the PCOS women was limited by
sample size with a lower than expected frequency ofMetS in these
women, although it still reached statistical significance. Clearly,
the discriminatory utility of the 3-miRNA signature should be
validated in larger cohorts.
While the clinical usefulness of measuring a circulating
miRNA for a PCOS related diagnostic purpose is currently
limited, the measurement of miRNAs in a clinical or ambulatory
setting using fast microfluidic nanoparticle-based devices is an
area of intense research (86) possibly enabling future use of
miRNAs for rapid tests. Our study adds novel information to the
growing body of evidence indicating a markedly different profile
of circulating miRNAs in diseases with elements of metabolic
dysfunction (PCOS, impaired glucose tolerance, obesity, non-
alcoholic fatty liver disease) (87, 88). Mapping out the miRNAs
altered during specific conditions could provide vital cues to
identifying their role as biomarkers and/or modulators of the
disease process. Future studies will deliver key indications of
common and separate pathways to metabolic disease.
In conclusion, we here report comprehensive profiling of
miRNAs in serum of PCOS patients and show that PCOS
patients have a profile of miRNAs deviating from Controls.
Moreover, our data demonstrate that the miRNA profile is
specific to subgroups of patients with PCOS: Normoandrogenic
PCOS women have circulating miRNAs that cluster differently
compared with hyperandrogenic PCOS women. In addition, a
three-candidate-miRNA biomarker signature can predict which
women among PCOS sub-phenotypes (based on normal and
increased free T levels) have a predisposition for developing
MetS. It will be relevant to extend these findings to search for
miRNAs related to fertility treatment outcomes.
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